"The US Agency for Healthcare Research and Quality recently released a 126 page review of MS disease modifying drugs concluding that the drugs don't really provide long term benefits for pwMS and "that meager information exists to guide patients and their physicians in making decisions about discontinuing DMTs. The authors stated that there’s little evidence suggesting long-term harms are any greater than short-term harms for patients taking DMTs. Similarly, they stated that there’s little evidence supporting long-term benefits from DMTs for patients with relapsing-remitting MS (RRMS)."

The names of the agency members who wrote this review remain anonymous ---however, the pharmaceutical companies and their representatives (MS researchers and "advocacy groups") are stating they are united in their criticism of the "shoddiness" of this non-industry sponsored report."


DMT Discontinuation Review Stirs MS Research Community | Multiple Sclerosis Discovery Forum
www.msdiscovery.org
News Synthesis | 14 Nov 2014 DMT Discontinuation Review Stirs MS Research Community The U.S. Agency for Healthcare Research and Quality (AHRQ) recently released a draft review on the evidence on discontinuation of disease-modifying therapies. Shocked by the apparent lack of expertise in the first dr…